Skip to Main Content
Table 4—

LIPC C → T variance and HL activity (units/l) after 30 weeks of treatment

GenotypenPlaceboAtorvastatin
10 mg80 mg
CC genotype 109     
 Baseline  437 ± 124 448 ± 140 447 ± 129  
 30 weeks  441 ± 139 402 ± 156* 348 ± 98*  
CT genotype 74     
 Baseline  352 ± 144 357 ± 121 366 ± 157  
 30 weeks  349 ± 137 319 ± 128* 280 ± 128*  
TT genotype 15     
 Baseline  224 ± 76 306 ± 104 257 ± 76  
 30 weeks  236 ± 137 273 ± 34 209 ± 45  
GenotypenPlaceboAtorvastatin
10 mg80 mg
CC genotype 109     
 Baseline  437 ± 124 448 ± 140 447 ± 129  
 30 weeks  441 ± 139 402 ± 156* 348 ± 98*  
CT genotype 74     
 Baseline  352 ± 144 357 ± 121 366 ± 157  
 30 weeks  349 ± 137 319 ± 128* 280 ± 128*  
TT genotype 15     
 Baseline  224 ± 76 306 ± 104 257 ± 76  
 30 weeks  236 ± 137 273 ± 34 209 ± 45  

Data are means ± SD.

*

P < 0.001, significantly different from baseline in each treatment group.

Close Modal

or Create an Account

Close Modal
Close Modal